CASI Pharmaceuticals Inc (NASDAQ:CASI) Historically, October is always a great month for a trend reversal on this name. I think we could see a strong reversal over the coming wks.
CASI Pharmaceuticals, Inc. (CASI) is still in bottoming mode. The technical indicators are looking better now for the stock. The MACD is starting to rise, confirming a bullish divergence has taken form and the Stochastic also has a bullish crossover. It might attempt to breakout above the $1.25 level on Monday and if it succeeds we should expect a strong move to...
CASI Pharmaceuticals Inc (NASDAQ:CASI) The daily chart is shaping up and I expect the next point of resistance to be at $2.25. At some point CASI will take off and never look back. I think that day will come soon and those buying at these prices will be thanking me down the road. Oppenheimer analyst Leland Gershell recently raised the price target on CASI to $6.00...
Pupm&Dump trading strategy idea.
$CASI is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $1,67;
stop-loss — $1,84;
take-profit — $1,32/MOC
Do not view this idea as a recommendation for trading or investing. It is...
Thursday's earnings report news has lit a fire under CASI Pharmaceuticals (NASDAQ: CASI) and I don't think it will be put out anytime soon. This looks like the start of a prolonged rally, one that could see this stock trading +400% higher than current levels according to Oppenheimer analyst Leland Gershell that yesterday raised the price target on CASI to $6.00...
Strong buying from COB/CEO in March at $2.06 and strong buying last year as well from same insider. Break 1.78, Stop signal 1.47. First target 2.33, Second target Momentum.
CASI Pharmaceuticals Inc (NASDAQ:CASI) moved up about 9.22% on strong volume last week and it looks like a lot of traders booked gains from the upwards run, but I did exactly the opposite. With the resistance level already identified on the charts and with the huge insider activity revealed, I used the pullback to take a big long position. Usually when insiders...
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor...
Interesting insider buying with a 3mil share purchase by the CEO
Will be on watch tomorrow for trend-line breakout
He Wei-Wu Chairman and CEO Mar 26 Buy 2.05 3,000,000 6,150,000 3,000,000
Hi friends
the daily analysis shows that it will experience with a high probability an uptrend but at the same time you have to be vigilant of the change towards the opposite direction
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO....
CASI saw a nice bump in after-hours trading Friday. Shares hit $1.88. Can the Oppenheimer analyst rating be enough of a catalyst to carry through this momentum into the week ahead is the biggest question. Great volume on Friday but is it all for nothing?
"What had sparked some excitement came in light of new analyst activity. Oppenheimer analyst Leland Gershell...
openinsider. com/search?q=CASI
insider BUY
CASI Zhang Larry Pres P - Purchase $1.90 +20,153 20,153 New +$38,291
CASI He Wei-Wu COB, CEO, 10% P - Purchase $1.90 +4,152,426 12,809,942 +48% +$7,889,609
CASI = CEO He Wei-wu Bought 4,152,426 shares × $1.90 = $7,889,609 Share count: 12,809,942 shares ..
If you want to understand where the money is invested and have returns on it, follow what the owners or internal managers perform ... The curriculum of each of them always leaves traces and makes it clear what they are capable of.
Wei-Wu He: this...
